- The FDA has given 510(k) clearance for Boston Scientific Corp’s (NYSE:BSX) Exalt Model B single-use bronchoscope for use in bedside procedures within the intensive care unit and operating room.
- The device can be used for a wide range of bronchoscopy procedures, including secretion management, airway intubation, percutaneous tracheostomy, double-lumen endotracheal tube placement, and biopsies.
- According to a news release, Boston Scientific offers the device in slim, regular, and large sizes.
- Exalt Model B joins the portfolio alongside Exalt Model D single-use duodenoscope, the LithoVue digital flexible ureteroscope, the SpyGlass DS direct visualization system, and the SpyGlass Discover digital catheter.
- Exalt Model B received CE mark approval in May, and Boston Scientific plans to begin the limited market release of the platform in the U.S. within the coming weeks.
- Price Action: BSX shares closed down 2.65% at $42.65 on Tuesday.
- Related content: Benzinga’s Full FDA Calendar.
Boston Scientific’s Exalt Model B Single-Use Bronchoscope Wins FDA Approval
The FDA has given 510(k) clearance for Boston Scientific Corp’s (NYSE:BSX) Exalt Model B single-use bronchoscope for use in bedside…
Related Posts
Stifel Maintains Buy on Monster Beverage, Lowers Price Target to $103
Stifel analyst Mark Astrachan maintains Monster Beverage (NASDAQ:MNST) with a Buy and lowers the price target from $107 to $103.
Fiesta Restaurant Group, Inc. Enters Into Definitive Agreement For The Sale Of Taco Cabana To an Affiliate Of Yadav Enterprises, Inc. For $85M
Sale Will Enable Increased Focus on Pollo Tropical Growth Opportunity
Transaction Proceeds to Fully Repay Term Loan Borrowings
Cash Balance as of June 27, 2021 of $67.6 million
Fiesta Restaurant Group, Inc.Sale Will Enable Increased Focus on Pollo Tropical Growth Opportunity
Transaction Proceeds to Fully Repay Term Loan Borrowings